Patents by Inventor Désiré Collen
Désiré Collen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9085617Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: GrantFiled: February 3, 2014Date of Patent: July 21, 2015Assignees: THROMBOGENICS N.V., VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW, LIFE SCIENCES RESEARCH PARTNERS VZWInventors: Jean-Marie Stassen, Peter Carmeliet, Desire Collen
-
Publication number: 20140178397Abstract: The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: ApplicationFiled: February 3, 2014Publication date: June 26, 2014Inventors: Jean-Marie STASSEN, Peter CARMELIET, Desire COLLEN
-
Patent number: 8758748Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: GrantFiled: December 20, 2010Date of Patent: June 24, 2014Assignees: Thrombogenics N.V., VLAAMS Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZWInventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
-
Publication number: 20130183310Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 5, 2013Publication date: July 18, 2013Inventors: Peter Carmeliet, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20130177565Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 5, 2013Publication date: July 11, 2013Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP), VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB)Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20130177564Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 5, 2013Publication date: July 11, 2013Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20120263710Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: May 14, 2012Publication date: October 18, 2012Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP), VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB)Inventors: Peter CARMELIET, Désiré Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20110288020Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.Type: ApplicationFiled: December 3, 2010Publication date: November 24, 2011Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
-
Publication number: 20110123525Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: ApplicationFiled: December 20, 2010Publication date: May 26, 2011Inventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
-
Patent number: 7888322Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.Type: GrantFiled: November 19, 2008Date of Patent: February 15, 2011Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZWInventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
-
Patent number: 7875704Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: GrantFiled: March 24, 2006Date of Patent: January 25, 2011Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZW, Thrombogenics N.V.Inventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
-
Patent number: 7727971Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.Type: GrantFiled: June 21, 2006Date of Patent: June 1, 2010Assignees: Life Sciences Research Partners VZW, Flanders Interuniversity Institute for Biotechnology (VIB)Inventors: Peter Carmeliet, Désiré Collen
-
Patent number: 7709450Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.Type: GrantFiled: June 20, 2002Date of Patent: May 4, 2010Assignees: Ludwig Institute for Cancer Research, Flanders Interuniversity Institute for BiotechnologyInventors: Ulf Eriksson, Xuri Li, Peter Carmeliet, Desire Collen
-
Publication number: 20100041601Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.Type: ApplicationFiled: November 19, 2008Publication date: February 18, 2010Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
-
Publication number: 20090238826Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 10, 2009Publication date: September 24, 2009Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Patent number: 7592314Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.Type: GrantFiled: June 4, 2007Date of Patent: September 22, 2009Assignees: Viaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research PartnersVZWInventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
-
Publication number: 20090162354Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: December 22, 2008Publication date: June 25, 2009Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)Inventors: Peter CARMELIET, Desire COLLEN, Sandro DE FALCO, Ruvo MENOTTI
-
Publication number: 20090074765Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: November 5, 2008Publication date: March 19, 2009Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Patent number: 7482004Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: GrantFiled: November 11, 2002Date of Patent: January 27, 2009Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie vzw, Life Sciences Research Partners vzw.Inventors: Peter Carmeliet, Désiré Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20080193455Abstract: The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: ApplicationFiled: March 24, 2006Publication date: August 14, 2008Inventors: Jean-Marie Stassen, Peter Carmeliet, Desire Collen